Abstract
Alzheimers disease (AD) is a progressive neurodegenerative disorder. To date, there is no cure for this disease. The FDA approved drugs, cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-Daspartate receptor antagonist (memantine) for the treatment of AD are symptomatically effective to some patients for short periods of time. Cholinesterase inhibitors exert additional pharmacological action beyond inhibition of cholinesterase that may maximize and prolong the effective of these drugs. The complexity of AD pathogenesis limits these drugs to correct every aspect of the disease. This problem has led to the current challenge in drug discovery to develop multitarget or combinational therapy. EGb 761 is a standardized extract of Ginkgo biloba leaves and has been shown to have potential benefit effects in various models of AD. Combination drug therapy, the use of drugs that act at different targets, may offer a novel strategy for management of AD. In this review, we evaluate mechanisms of individual drugs for treatment of AD and summarize the combination studies between cholinesterase inhibitors and NMDA receptor antagonist memantine, cholinesterase inhibitors and EGb 761 in experimental models and clinical trials.
Keywords: Alzheimer's disease, combination therapy, Ginkgo biloba
Central Nervous System Agents in Medicinal Chemistry
Title: Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Volume: 8 Issue: 4
Author(s): Roongpetch Keowkase and Yuan Luo
Affiliation:
Keywords: Alzheimer's disease, combination therapy, Ginkgo biloba
Abstract: Alzheimers disease (AD) is a progressive neurodegenerative disorder. To date, there is no cure for this disease. The FDA approved drugs, cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-Daspartate receptor antagonist (memantine) for the treatment of AD are symptomatically effective to some patients for short periods of time. Cholinesterase inhibitors exert additional pharmacological action beyond inhibition of cholinesterase that may maximize and prolong the effective of these drugs. The complexity of AD pathogenesis limits these drugs to correct every aspect of the disease. This problem has led to the current challenge in drug discovery to develop multitarget or combinational therapy. EGb 761 is a standardized extract of Ginkgo biloba leaves and has been shown to have potential benefit effects in various models of AD. Combination drug therapy, the use of drugs that act at different targets, may offer a novel strategy for management of AD. In this review, we evaluate mechanisms of individual drugs for treatment of AD and summarize the combination studies between cholinesterase inhibitors and NMDA receptor antagonist memantine, cholinesterase inhibitors and EGb 761 in experimental models and clinical trials.
Export Options
About this article
Cite this article as:
Keowkase Roongpetch and Luo Yuan, Mechanism of CNS Drugs and their Combinations for Alzheimers Disease, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848166
DOI https://dx.doi.org/10.2174/187152408786848166 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases
Current Stem Cell Research & Therapy Spectroscopic and Theoretical Approaches for the Determination of Heparin Saccharide Structure and the Study of Protein-Glycosaminoglycan Complexes in Solution
Current Medicinal Chemistry Classic β-Amyloid Deposits Cluster Around Large Diameter Blood Vessels Rather than Capillaries in Sporadic Alzheimers Disease
Current Neurovascular Research Editorial [Celebrating the Fifth Year Anniversary of Current Alzheimer Research(Guest Editor: Debomoy K. Lahiri)]
Current Alzheimer Research Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite
Current Medicinal Chemistry Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction
Medicinal Chemistry The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology Thrombin: A Potential Proinflammatory Mediator in Neurotrauma and Neurodegenerative Disorders
Current Drug Targets - Inflammation & Allergy Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents
Current Medicinal Chemistry - Central Nervous System Agents Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology